Can prostate cancer patients skip hormone therapy? new trial tests SBRT alone
NCT ID NCT06397703
First seen Feb 01, 2026 · Last updated Jun 23, 2026 · Updated 26 times
Summary
This phase 2 trial is for men with unfavorable intermediate-risk prostate cancer. Participants choose between standard care (6 months of hormone therapy plus high-dose radiation) or radiation alone. The goal is to see if skipping hormone therapy still keeps cancer from returning. About 392 men will be followed for up to 5 years with regular biopsies and PSA tests.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
NYU Langone Health
RECRUITINGNew York, New York, 10016, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Stereotactic body radiation therapy (SBRT) and androgen deprivation therapy (ADT) using leuprolide, degarelix, or relugolix
What this could lead to
If successful, this could show that SBRT alone is as effective as SBRT plus hormone therapy for controlling intermediate-risk prostate cancer, potentially sparing many men from hormone side effects.
What could go wrong
This is a phase 2 trial with 392 participants, so results are not definitive. The study relies on patient choice rather than random assignment, which may bias outcomes. Long-term follow-up is needed to confirm cancer control.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.